ArticleMikrochimica acta2026
A rime-like Au-Pt nanostructured film and polyaniline-MIP based electrochemical sensor for olanzapine detection.
Article in Mikrochimica acta, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
An electrochemical (EC) molecularly imprinted polymer (MIP) sensor for therapeutic drug monitoring of olanzapine (OLZ) has been developed. A “rime-like” gold-platinum nanostructured film (Au-Pt NF) was fabricated on a screen-printed carbon electrode (SPCE) via an one-step hydrogen bubble dynamic template (HBDT) method, followed by electropolymerization of a polyaniline-based MIP. The Au-Pt NF/SPCE served as an ideal three-dimensional conductive substrate with a large active area and enhanced electron-transfer capability, endowing the specific MIP sensor with high sensitivity. Using [Fe(CN)6]3−/4− as a redox probe, the sensor quantified OLZ by the decrease in differential pulse voltammetry current caused by target binding. It exhibited two linear ranges (0.005–0.4 µM and 0.4–10 µM) with a detection limit of 0.94 nM, and demonstrated high selectivity, reproducibility, and stability. The sensor achieved recoveries of 96.7–102.7% for OLZ in tablets, urine, and whole blood. This work provides a reliable, all-EC sensing platform with strong potential for rapid OLZ monitoring in clinical settings.
Indexed as
Identifiers
41811539What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.